Email Alert RSS English | 中文
Advanced Search
et alRadiotherapy for soft-tissue sarcoma:clinical practice and progress[J]. Chin J Clin Med, 2019, 26(3): 326-331. DOI: 10.12025/j.issn.1008-6358.2019.20190636
Citation: et alRadiotherapy for soft-tissue sarcoma:clinical practice and progress[J]. Chin J Clin Med, 2019, 26(3): 326-331. DOI: 10.12025/j.issn.1008-6358.2019.20190636
shu

Radiotherapy for soft-tissue sarcoma:clinical practice and progress

More Information
  • Received Date: April 27, 2019
  • Revised Date: April 27, 2019
    Graphical Abstract
    • Abstract
  • he treatment strategies for soft-tissue sarcoma (STS) largely depend on the histological subtype, differentiation, and the origin of the disease. Radiotherapy is an important component of the multi-modality management for STS. For STS of the extremities, surgery followed by adjuvant radiotherapy can produce identical disease control and overall survival rates as compared to amputation, but ensures function preservation. Pre-operative radiotherapy improves disease control for retroperitoneal STS. Adjuvant or definitive radiation therapy is a vital component for STS of the head and neck region. Pre-operative radiotherapy, as compared to post-operative radiation, produces similar disease control rates yet reduces late treatment-induced toxicities. Furthermore, radiotherapy is the mainstay treatment modality for inoperable or unresectable STS. Novel radiotherapy technology such as particle beam radiation therapy (PBRT) can not only reduce radiation-induced toxicities but also improve disease control especially for radioresistant subtypes, due to its high precision and improved biological effectiveness. PBRT is also a potentially effective option for salvaging STS patients who failed previous course of radiotherapy, or for patients diagnosed with radiation-induced secondary primary STS
    • FullText(HTML)
    • References (53)
  • [1]
    Board PDQATE. Adult Soft Tissue Sarcoma Treatment (PDQ(R)): Health Professional Version. PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); 2002.
    [2]
    Shah C, Verma V, Takiar R, et al. Radiation Therapy in the Management of Soft Tissue Sarcoma: A Clinician''s Guide to Timing, Techniques, and Targets. American journal of clinical oncology. 2016;39(6):630-5.
    [3]
    Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of softtissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982:196:305-15.
    [4]
    Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998;16(1):197-203.
    [5]
    Koshy M, Rich SE, Mohiuddin MM. Improved survival with radiation therapy in high-grade soft tissue sarcomas of the extremities: a SEER analysis. International journal of radiation oncology, biology, physics. 2010;77(1):203-9.
    [6]
    Kepka L, DeLaney TF, Suit HD, Goldberg SI. Results of radiation therapy for unresected soft-tissue sarcomas. International journal of radiation oncology, biology, physics. 2005;63(3):852-9.
    [7]
    乐紫妤，刘勇. 重离子肿瘤放射生物学的研究进展. 中华放射肿瘤学杂志2015难第5期
    [8]
    Kanai T, Endo M, Minohara S, Miyahara N, Koyama-ito H, Tomura H, et al. Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. International journal of radiation oncology, biology, physics. 1999;44(1):201-10
    [9]
    Tsujii H KT, Baba M. Clinical advantages of carbon-ion radiotherapy. New J Phys. 2008;10(075009).
    [10]
    Serizawa I, Kagei K, Kamada T, Imai R, Sugahara S, Okada T, et al. Carbon ion radiotherapy for unresectable retroperitoneal sarcomas. International journal of radiation oncology, biology, physics. 2009;75(4):1105-10.
    [11]
    Jingu K, Tsujii H, Mizoe JE, Hasegawa A, Bessho H, Takagi R, et al. Carbon ion radiation therapy improves the prognosis of unresectable adult bone and soft-tissue sarcoma of the head and neck. International journal of radiation oncology, biology, physics. 2012;82(5):2125-31.
    [12]
    Sugahara S, Kamada T, Imai R, Tsuji H, Kameda N, Okada T, et al. Carbon ion radiotherapy for localized primary sarcoma of the extremities: results of a phase I/II trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2012;105(2):226-31.
    [13]
    Matsumoto K, Imai R, Kamada T, Maruyama K, Tsuji H, Tsujii H, et al. Impact of carbon ion radiotherapy for primary spinal sarcoma. Cancer. 2013;119(19):3496-503.
    [14]
    Yang J, Gao J, Hu J, et al. Clinical outcome of carbon ion re-irradiation therapy for radiotherapy recurrent/radiation-induced sarcomas in head and neck. Cancer Med. 2019; Accepted
    [15]
    Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996 Mar;14(3):859-68.
    [16]
    Pisters PW, Harrison LB, Woodruff JM, et al. A prospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk. J Clin Oncol. 1994 Jun;12(6):1150-5.
    [17]
    Naghavi AO, Fernandez DC, Mesko N, et al. American Brachytherapy Society consensus statement for soft tissue sarcoma brachytherapy. Brachytherapy. 2017 May - Jun;16(3):466-489.
    [18]
    Pisters PWT, Harrison LB, Leung DHY, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14:859–868
    [19]
    O’Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial. Lancet 2002;359:2235–2241
    [20]
    Correa R1, Gómez-Millán J, Lobato M, et al. Radiotherapy in soft-tissue sarcoma of the extremities. Clin Transl Oncol 2018;20:1127-1135
    [21]
    Fiore M, Ford S, Callegaro D, et al. Adequate local control in high-risk soft tissue sarcoma of the extremity treated with surgery alone at a reference centre: should radiotherapy still be a stan- dard? Ann Surg Oncol 2018;25:1536-1543
    [22]
    Tran LM, Mark R, Meier R, Calcaterra TC, Parker RG. Sarcomas of the head and neck. Prognostic factors and treatment strategies. Cancer. 1992;70(1):169-77.
    [23]
    Barker JL, Jr., Paulino AC, Feeney S, McCulloch T, Hoffman H. Locoregional treatment for adult soft tissue sarcomas of the head and neck: an institutional review. Cancer journal. 2003;9(1):49-57.
    [24]
    Le QT, Fu KK, Kroll S, Fitts L, Massullo V, Ferrell L, et al. Prognostic factors in adult soft-tissue sarcomas of the head and neck. International journal of radiation oncology, biology, physics. 1997;37(5):975-84.
    [25]
    Bentz BG, Singh B, Woodruff J, Brennan M, Shah JP, Kraus D. Head and neck soft tissue sarcomas: a multivariate analysis of outcomes. Annals of surgical oncology. 2004;11(6):619-28.
    [26]
    Tejani MA, Galloway TJ, Lango M, Ridge JA, von Mehren M. Head and neck sarcomas: a comprehensive cancer center experience. Cancers. 2013;5(3):890-900.
    [27]
    Galy-Bernadoy C, Garrel R. Head and neck soft-tissue sarcoma in adults. European annals of otorhinolaryngology, head and neck diseases. 2016;133(1):37-42.
    [28]
    Eeles RA, Fisher C, A''Hern RP, Robinson M, Rhys-Evans P, Henk JM, et al. Head and neck sarcomas: prognostic factors and implications for treatment. British journal of cancer. 1993;68(1):201-7.
    [29]
    Mendenhall WM, Mendenhall CM, Werning JW, Riggs CE, Mendenhall NP. Adult head and neck soft tissue sarcomas. Head & neck. 2005;27(10):916-22.
    [30]
    de Bree R, van der Waal I, de Bree E, Leemans CR. Management of adult soft tissue sarcomas of the head and neck. Oral oncology. 2010;46(11):786-90
    [31]
    Andra C, Rauch J, Li M, Ganswindt U, Belka C, Saleh-Ebrahimi L, et al. Excellent local control and survival after postoperative or definitive radiation therapy for sarcomas of the head and neck. Radiation oncology. 2015;10:140.
    [32]
    Vitzthum LK, Brown LC, Rooney JW, Foote RL. Head and Neck Soft Tissue Sarcomas Treated with Radiation Therapy. Rare tumors. 2016;8(2):6165.
    [33]
    Gil Z, Patel SG, Singh B, Cantu G, Fliss DM, Kowalski LP, et al. Analysis of prognostic factors in 146 patients with anterior skull base sarcoma: an international collaborative study. Cancer. 2007;110(5):1033-41
    [34]
    O''Sullivan B, Gullane P, Irish J, Neligan P, Gentili F, Mahoney J, et al. Preoperative radiotherapy for adult head and neck soft tissue sarcoma: assessment of wound complication rates and cancer outcome in a prospective series. World journal of surgery. 2003;27(7):875-83.
    [35]
    NCCN Clinical Practice Guidelines in Oncology, Soft-Tissue Sarcoma. https://www.nccn.org/professionals/physician_gls/default.aspx#sarcoma. Accessed on April 29, 2019
    [36]
    Stoeckle E, Coindre JM, Bonvalot S, et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer 2001;92:359–68.
    [37]
    Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol 2009;27:24–30.
    [38]
    Bates JE, Dhakal S, Mazloom A, Constine LS. The benefit of adjuvant radiotherapy in high-grade nonmetastatic retroperitoneal soft tissue sarcoma: a SEER analysis. Am J Clin Oncol. 2018 Mar;41(3):274-279.
    [39]
    Tseng WH, Martinez SR, Do L, et al. Lack of survival benefit following adjuvant radiation in patients with retroperitoneal sarcoma: a SEER analysis. J Surg Res. 2011;168:e173-e180.
    [40]
    Ballo MT, Zagars GK, Pollock RE, et al. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys. 2007;67:158–163.
    [41]
    Pezner RD, Liu A, Chen YJ, et al. Full-dose adjuvant postoperative radiation therapy for retroperitoneal sarcomas. Am J Clin Oncol. 2011; 34:511–516.
    [42]
    Bishop AJ, Zagars GK, Torres KE, et al. Combined modality management of retroperitoneal sarcomas: a single-institution series of 121 patients. Int J Radiat Oncol Biol Phys. 2015;93:158–165.
    [43]
    Le Péchoux C,Musat E,Baey C,et al. Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma? Ann Oncol. 2013;24:832–837.
    [44]
    Baldini EH, Wang D, Haas RL, et al. Treatment guidelines for preoperative radiation therapy for retroperitoneal sarcoma: preliminary consensus of an international expert panel. Int J Radiat Oncol Biol Phys 2015;92:602–12.
    [45]
    Available at: https://clinicaltrials.gov/ct2/show/NCT01344018. Accessed May 30, 2016.
    [46]
    Sarcoma specialists from the United Kingdom, including members of the British Sarcoma Group and NHS England Sarcoma Clinical Reference Group, issued guidelines on management of soft-tissue sarcoma in 2016. 2016.
    [47]
    Giannini L, Incandela F, Fiore M, et al. Radiation-Induced Sarcoma of the Head and Neck: A Review of the Literature. Frontiers in oncology. 2018;8:449.
    [48]
    Catton C, Davis A, Bell R, et al. Soft tissue sarcoma of the extremity. Limb salvage after failure of combined conservative therapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1996;41(3):209-14.
    [49]
    Torres MA, Ballo MT, Butler CE, et al. Management of locally recurrent soft-tissue sarcoma after prior surgery and radiation therapy. International journal of radiation oncology, biology, physics. 2007;67(4):1124-9.
    [50]
    Rosko AJ, Birkeland AC, Chinn SB, et al. Survival and Margin Status in Head and Neck Radiation-Induced Sarcomas and De Novo Sarcomas. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2017;157(2):252-9.
    [51]
    Tan A, Ngan SY, Choong PF. Post-radiation sarcoma of the neck treated with re-irradiation followed by wide excision. World journal of surgical oncology. 2006;4:69.
    [52]
    Graham JD, Robinson MH, Harmer CL. Re-irradiation of soft-tissue sarcoma. Br J Radiol. 1992 Feb;65(770):157-61.
    [53]
    Yang J, Gao J, Wu X, et al. Salvage Carbon Ion Radiation Therapy for Locally Recurrent or Radiation-Induced Second Primary Sarcoma of the Head and Neck. Journal of Cancer. 2018;9(12):2215-23.
    • Related Articles

  • Related Articles

    [1]CHEN Yin, ZHANG Zhitian, LIU Jiaojiao, YAN Hongmei, GUO Shanshan. Clinical research progress on the relationship between vitamin D and glucose metabolism disorders[J]. Chin J Clin Med. DOI: 10.12025/j.issn.1008-6358.2025.20241157
    [2]WANG Cheng-gang, GONG Gao-quan. Clinical application progress of interventional diagnosis and treatment for retroperitoneal tumor[J]. Chin J Clin Med, 2021, 28(2): 323-327. DOI: 10.12025/j.issn.1008-6358.2021.20201778
    [3]MA Qiong, SHI Xiu-dong, LU Yang, SHI Yu-xin. Research progress on clinical and imaging study of novel coronavirus pneumonia[J]. Chin J Clin Med, 2020, 27(1): 23-26. DOI: 10.12025/j.issn.1008-6358.2020.20200340
    [4]Research progress of prognostic factors and prediction tools for retroperitoneal soft tissue sarcomas[J]. Chin J Clin Med, 2019, 26(3): 332-339. DOI: 10.12025/j.issn.1008-6358.2019.20190147
    [5]Interpretation of soft tissue sarcoma (retroperitoneal sarcoma) section in NCCN clinical practice guideline[J]. Chin J Clin Med, 2019, 26(3): 321-325. DOI: 10.12025/j.issn.1008-6358.2019.20190576
    [6]HAO Jia-tao, WANG Peng, SHOU Juan. Research progress of clinical features and therapy of late life depression[J]. Chin J Clin Med, 2019, 26(2): 297-302.
    [7]TIAN Peng-sheng, MA Hong-chang. Research progress in clinical application of cerebral tissue oxygen saturation[J]. Chin J Clin Med, 2019, 26(2): 292-296.
    [8]YU Min-cheng, HU Bo, FU Pei-yao, YANG Zhang-fu, TANG Wei-guo, SUN Hai-xiang, XU Yang. Research progress on adverse events in clinical treatment of anti-PD-1/PD-L1 antibodies[J]. Chin J Clin Med, 2018, 25(4): 625-631. DOI: 10.12025/j.issn.1008-6358.2018.20180320
    [9]Autophagy in clinical therapy of tumor: research progress[J]. Chin J Clin Med, 2017, 24(5): 797-801. DOI: 10.12025/j.issn.1008-6358.2017.20170190
    [10]Recent progress on development and clinical application of detachable microcatheter in the treatment of cerebral A[J]. Chin J Clin Med, 2017, 24(1): 154-158. DOI: 10.12025/j.issn.1008-6358.2017.20160944

  • Cited by

    Periodical cited type(10)

    1. 张灿，张国楠，王登凤，余健，徐世强，石宇. 子宫颈癌放射治疗后盆腔侧壁放疗相关间叶源性软组织肉瘤1例. 实用妇产科杂志. 2024(02): 159-160 .
    2. 贺潇，晁生武. 下肢巨大滑膜肉瘤合并Ⅰ型神经纤维瘤病一例. 中国美容整形外科杂志. 2023(04): 256-257 .
    3. 李小军，张雁山，叶延程，陈东基，李莎，潘鑫. 碳离子治疗二次术后放疗后复发小腿黏液样脂肪肉瘤1例. 现代肿瘤医学. 2022(02): 314-318 .
    4. 孙宁宁，彭丽丽，郭亚鹏，魏亚红，张洪珍. 乳腺癌术后放射治疗诱发恶性神经鞘瘤1例. 华北理工大学学报(医学版). 2022(01): 72-74 .
    5. 王湘琴，王细军，翟一霖. 身心并重干预模式在软组织肉瘤化疗患者中的应用. 齐鲁护理杂志. 2022(07): 135-138 .
    6. 方菲，原浩，韦燕. 调强放射治疗联合安罗替尼治疗转移性四肢软组织肉瘤的临床观察. 中国现代医药杂志. 2022(06): 57-59 .
    7. 徐婉琳，李柳宁. 李柳宁教授从虚痰瘀论治软组织肉瘤思想探析. 四川中医. 2021(10): 1-4 .
    8. 王子航，孟兴凯，张俊晶. 胰腺多形性未分化肉瘤:病例报告与文献回顾. 中国普通外科杂志. 2020(03): 333-340 .
    9. 沈舞婷，马争，郭少嘉，陈惠鹏，黄兴. 医用电子直线加速器建设项目屏蔽设计. 职业与健康. 2020(11): 1458-1461 .
    10. 阎伟伟，丁玉芹，戴辰晨，周建军，曾蒙苏，陆维琪. 弥散加权成像-表观扩散系数图纹理分析对腹膜后去分化及高分化脂肪肉瘤的鉴别诊断价值. 中国临床医学. 2019(04): 606-610 . 本站查看

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (2399) PDF downloads (828) Cited by(12)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Links

    沪ICP备16009103号-3

    沪公网安备 31010402004907号

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return